Molecular targeted therapy for anticancer treatment

HY Min, HY Lee - Experimental & molecular medicine, 2022 - nature.com
Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

Targeted drug delivery strategies for precision medicines

MT Manzari, Y Shamay, H Kiguchi, N Rosen… - Nature Reviews …, 2021 - nature.com
Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

LB Kilburn, DA Khuong-Quang, JR Hansford, D Landi… - Nature medicine, 2024 - nature.com
BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade
glioma (pLGG). Arm 1 (n= 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial …

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

C Zhu, X Guan, X Zhang, X Luan, Z Song, X Cheng… - Molecular cancer, 2022 - Springer
Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …

ERK: a double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer

R Sugiura, R Satoh, T Takasaki - Cells, 2021 - mdpi.com
The RAF/MEK/ERK signaling pathway regulates diverse cellular processes as exemplified
by cell proliferation, differentiation, motility, and survival. Activation of ERK1/2 generally …

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

ME Bahar, HJ Kim, DR Kim - Signal transduction and targeted therapy, 2023 - nature.com
Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

RAF-MEK-ERK pathway in cancer evolution and treatment

R Ullah, Q Yin, AH Snell, L Wan - Seminars in cancer biology, 2022 - Elsevier
Abstract The RAF-MEK-ERK signaling cascade is a well-characterized MAPK pathway
involved in cell proliferation and survival. The three-layered MAPK signaling cascade is …

Targeting the MAPK pathway in KRAS-driven tumors

M Drosten, M Barbacid - Cancer cell, 2020 - cell.com
KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy

O Rodak, MD Peris-Díaz, M Olbromski… - Cancers, 2021 - mdpi.com
Simple Summary The abundance and the dynamic of the studies on NSCLC require
frequent summaries of the current achievements in the field. In our review, we aimed to …

Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

Y Liu, Y Li, Y Wang, C Lin, D Zhang, J Chen… - Journal of Hematology & …, 2022 - Springer
Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein
tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis …